14 completed, 9 recruiting, 5 terminated, 4 active not recruiting. 35 Phase 1, 17 Phase 2.
Follow Neurofibrosarcoma: new trials by email Literature Review of Neurofibrosarcoma trials Research Report on Neurofibrosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor BMS-986504 - Malignant Peripheral Nerve Sheath Tumors, MPNST | Phase 1 / Phase 2 | Recruiting | Ankit Mangla, MD | 17 | 2026-08-01 | 2026-08-11 |
| Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST APG-115, Selumetinib - Malignant Peripheral Nerve Sheath Tumor (MPNST), Neurofibromatosis 1 (NF1) | Phase 1 / Phase 2 | Recruiting | AeRang Kim | 45 | 2026-06-01 | 2026-07-27 |
| A Study of DEG6498 in Participants With Solid Tumors DEG6498 - Malignant Neoplasms | Phase 1 | Recruiting | Degron Therapeutics Co. | 100 | 2025-11-13 | 2026-06-30 |
| Using CICS-1 and SPM-011 and ［18F］FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA BNCT, ［18F］FBPA - Thoracic Solid Malignant Tumor | Phase 1 / Phase 2 | Enrolling by invitation | Stella Pharma Corporation | 30 | 2025-04-10 | 2025-11-19 |
| NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) Surgical resection, Proton beam radiation therapy, Pazopanib - Adipocytic Neoplasm, Liposarcoma | Phase 1 / Phase 2 | Recruiting | St. Jude Children's Research Hospital | 139 | 2024-03-27 | 2026-08-03 |
| SPEARHEAD-3 Pediatric Study Afamitresgene autoleucel - Synovial Sarcoma, Malignant Peripheral Nerve Sheath Tumor (MPNST) | Phase 1 / Phase 2 | Recruiting | USWM CT, LLC | 20 | 2023-09-01 | 2026-08-11 |
| Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors TNG462, Pembrolizumab - Locally Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | Tango Therapeutics, Inc. | 225 | 2023-05-26 | 2026-09-08 |
| B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) Fludarabine, Cyclophosphamide, MESNA - Pediatric Solid Tumor, Osteosarcoma | Phase 1 | Recruiting | St. Jude Children's Research Hospital | 48 | 2022-07-06 | 2026-05-19 |
| Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion MRTX1719 - Mesothelioma, Non Small Cell Lung Cancer | Phase 1 | Recruiting | Bristol-Myers Squibb | 336 | 2022-06-09 | 2026-09-02 |
| Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors TNG908 - Locally Advanced Solid Tumor | Phase 1 / Phase 2 | Terminated | Tango Therapeutics, Inc. | 110 | 2022-03-23 | 2026-04-15 |
| A Clinical Trial to Evaluate the Safety and Efficacy of AL2846 Capsules in Chinese Patients With Type I Neurofibromatosis AL2846 capsules - Neurofibromatosis and Malignant Peripheral Nerve Sheath Tumors | Phase 1 / Phase 2 | Terminated | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 22 | 2021-09-07 | 2024-03-21 |
| A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients Selinexor - Soft Tissue Sarcoma, Malignant Peripheral Nerve Sheath Tumor (MPNST) | Phase 1 | Completed | University Health Network, Toronto | 56 | 2021-03-29 | 2025-05-29 |
| Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma Selinexor, Ixazomib - Liposarcoma, Malignant Peripheral Nerve Sheath Tumors | Phase 1 | Withdrawn | Matthew Ingham | 2020-11-01 | 2020-11-27 | |
| Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors Metarrestin - Advanced Solid Tumors, Metastatic Pancreatic Cancer | Phase 1 | Recruiting | National Cancer Institute (NCI) | 116 | 2020-10-27 | 2026-11-09 |
| Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma Definitive Surgical Resection, Nanoplexed Poly I:C BO-112, Nivolumab - Leiomyosarcoma, Malignant Peripheral Nerve Sheath Tumor | Phase 1 | Active not recruiting | Jonsson Comprehensive Cancer Center | 14 | 2020-10-14 | 2026-03-10 |
| B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults second generation 4-1BBζ B7H3-EGFRt-DHFR, second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tG, Pembrolizumab - Pediatric Solid Tumor, Germ Cell Tumor | Phase 1 | Active not recruiting | Seattle Children's Hospital | 68 | 2020-07-13 | 2026-04-28 |
| EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults second generation 4-1BBζ EGFR806-EGFRt, second generation 4-1BBζ EGFR806-EGFRt and a second generation 4 1BBζ CD19-Her2tG - Pediatric Solid Tumor, Germ Cell Tumor | Phase 1 | Active not recruiting | Seattle Children's Hospital | 44 | 2019-06-18 | 2026-10-08 |
| A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors Phase 1b: APG-115+pembrolizumab - Unresectable or Metastatic Melanoma or Advanced Solid Tumors, Melanoma | Phase 1 / Phase 2 | Active not recruiting | Ascentage Pharma Group Inc. | 230 | 2018-08-29 | 2025-08-07 |
| Vaccine Therapy in Treating Patients with Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery Computed Tomography, Laboratory Biomarker Analysis, Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter - Metastatic Malignant Peripheral Nerve Sheath Tumor, Neurofibromatosis Type 1 | Phase 1 | Completed | Mayo Clinic | 9 | 2017-03-22 | 2024-09-27 |
| Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study - Advanced Soft Tissue Sarcoma, Locally Advanced Angiosarcoma | Phase 1 | Completed | OHSU Knight Cancer Institute | 16 | 2017-03-10 | 2023-08-16 |
Showing 20 of 35. Sign in to see all of them.
Sarcoma (22) · Sarcoma, Synovial (15) · Leiomyosarcoma (12) · Rhabdomyosarcoma (12) · Histiocytoma, Malignant Fibrous (11) · Liposarcoma (10) · Osteosarcoma (9) · Fibrosarcoma (8) · Sarcoma, Ewing (8) · Hemangiosarcoma (7) · Dermatofibrosarcoma (6) · Neuroblastoma (6) · Desmoplastic Small Round Cell Tumor (5) · Sarcoma, Alveolar Soft Part (5)
Neoplasms by Histologic Type (35) · Neoplasms, Connective Tissue (35) · Neoplasms, Fibrous Tissue (35) · Neoplasms, Nerve Tissue (35) · Nervous System Diseases (35) · Nervous System Neoplasms (35) · Neurofibroma (35) · Neuromuscular Diseases (35) · Peripheral Nervous System Diseases (35) · Peripheral Nervous System Neoplasms (35) · Neoplasms, Connective and Soft Tissue (34) · Nerve Sheath Neoplasms (34) · Neoplasms (33) · Fibrosarcoma (27) · Neoplasms, Muscle Tissue (19)
Doxorubicin (3) · pazopanib (3) · pembrolizumab (3) · selinexor (3) · Ifosfamide (2) · Magnetic Resonance Spectroscopy (2) · Radiotherapy (2) · Sirolimus (2) · 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (1) · AZD 6244 (1) · BO-112 (1) · Biopsy (1) · Celecoxib (1) · Chemotherapy, Adjuvant (1) · Cyclophosphamide (1)
National Cancer Institute (NCI) (6) · European Organisation for Research and Treatment of Cancer - EORTC (2) · Seattle Children's Hospital (2) · St. Jude Children's Research Hospital (2) · Tango Therapeutics, Inc. (2) · AeRang Kim (1) · Ankit Mangla, MD (1) · Ascentage Pharma Group Inc. (1) · Bristol-Myers Squibb (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Degron Therapeutics Co. (1) · Gulam Manji (1) · Jennerex Biotherapeutics (1) · Jonsson Comprehensive Cancer Center (1) · Matthew Ingham (1)
United States (28) · France (3) · China (2) · Denmark (2) · Australia (1) · Belgium (1) · Canada (1) · Germany (1) · Japan (1) · Netherlands (1) · Russia (1) · Spain (1) · United Kingdom (1)
AeRang Kim, MD, PhD (2) · Aaron H. Wolfson, MD (1) · Albiruni Razak, M.D. (1) · Ankit Mangla, MD (1) · Brigitte C Widemann, M.D. (1) · Brigitte Widemann, MD (1) · Catherine Albert, MD (1) · Chris DeRenzo, MD (1) · Crystal L Mackall, M.D. (1) · David M Loeb, MD, PhD (1) · Dusica Babovic-Vuksanovic, MD (1) · Fiorella Iglesias Cardenas, MD (1) · Gulam A. Manji, MD (1) · Jacob Verweij, MD, PhD (1)
PMID 11705489, PMID 12528778, PMID 12957454, PMID 15010069, PMID 15592836, PMID 19088049, PMID 23382028, PMID 25858498, PMID 30410720, PMID 31401903, PMID 32089640, PMID 33641042, PMID 34321280, PMID 39255444, PMID 39756156
K08CA245181 (1), N01CM00071 (1), N01CM62206 (1), P30CA008748 (1), P30CA014599 (1), U01CA069856 (1), U10CA180821 (1)